Imakethe yamasheya, ukuhwebelana kwamasheya namuhla
Ukucaphuna kwamasheya ezinkampanini ezingu-71229 ngesikhathi sangempela.
Imakethe yamasheya, ukuhwebelana kwamasheya namuhla

Izingcaphuno ze-Stock

Ukucaphuna kwamasheya ku-inthanethi

Umlando ucaphuna umlando

I-capital market capital

Izigaba ze-Stock

Inzuzo evela kumasheya enkampani

Imibiko yezezimali

Amanani wokulinganisa wezinkampani. Kukuphi ukutshalwa imali?

Recro Pharma, Inc. ikhanda lemakethe

Umthamo wokuhweba kwamasheya Recro Pharma, Inc. namhlanje nomlando we-capital of Recro Pharma, Inc. kusukela ekuqaleni kokuhweba kwamasheya REPH esitokisini samasheya.
Engeza kumawijethi
Ingeziwe kumawijethi

Recro Pharma, Inc. izimali ezinkulu

Namuhla imali yemakethe ye- Recro Pharma, Inc. ingu-118 490 816 US dollar.
-3 103 336 $ (-2.55%)
ukuguqulwa komnotho kusukela izolo

Recro Pharma, Inc. capitalization namuhla ithathwa njengesamba sazo zonke izingcaphuno zesitoko Recro Pharma, Inc. zemali esikhishwe. Imininingwane ye- Recro Pharma, Inc. capitalisation ithathwe emithonjeni evulekile. Ungathola imali engu- Recro Pharma, Inc. capitalization yanamuhla ngokususelwa ekuthengisweni kwale ntengo yesitoko emakethe yamasheya wesitoko. Recro Pharma, Inc., capitalisation - 118 490 816 amadola aseMelika.

Recro Pharma, Inc. ivolumu yokuhweba

Namuhla inani lamasheya okuhweba Recro Pharma, Inc. lilinganiselwa ku-29 724 US dollar.
-45 271 $ (-60.37%)
ushintsho lwevolumu yezohwebo kusukela izolo

Recro Pharma, Inc. amanani wokuhweba namuhla afinyelela ku- $ 29 724. Recro Pharma, Inc. kwenzeka ekushintshanisweni okuhlukahlukene kwesilinganiso sempahla. Ishadi lokuhweba nsuku zonke le- Recro Pharma, Inc. likuwebhusayithi yethu. Recro Pharma, Inc. cap yemakethe iyehla.

Bonisa:
Ukuze

Recro Pharma, Inc. ishadi lesikhwama semakethe

Ukushintshwa kwe- Recro Pharma, Inc. capitalization ngesonto 6.06%. Ngokudlula kwenyanga, Recro Pharma, Inc. isishintshwe yi- 0%. Recro Pharma, Inc. Ushintsho lokongamela lonyaka 0%. Recro Pharma, Inc., capitalization manje - 118 490 816 amadola aseMelika.

Iviki Inyanga izinyanga 3 Unyaka Iminyaka emithathu

Recro Pharma, Inc. umlando wemali enkulu

Usuku I-Capitalization
I-capitalisation (capital capital) yi-value yemakethe yawo wonke amasheya ezinkampanini ezithengiswa nge-stock exchange. Izimali zamakethe zilingana nentengo yamasheya okwandiswe inani lamasheya alingisiwe.
21/03/2022 118 490 816 $
18/03/2022 121 594 152 $
17/03/2022 115 376 208 $
16/03/2022 115 105 368 $
15/03/2022 112 848 400 $
14/03/2022 113 508 560 $
12/03/2022 111 719 920 $

Ishadi levolumu ye-Recro Pharma, Inc.

Iviki Inyanga izinyanga 3 Unyaka Iminyaka emithathu

Recro Pharma, Inc. idatha yomlando wevolumu

Usuku Ivolumu (24h)
Umthamo wokuhweba we-Recro Pharma, Inc. amasheya yinani eliphelele lazo zonke izinkokhelo ngezabelo ze-REPH ezithengisiwe futhi zithengiswa ngedethi ekhethiwe.
21/03/2022 29 724 $
18/03/2022 74 995 $
17/03/2022 10 977 $
16/03/2022 76 742 $
15/03/2022 26 737 $
14/03/2022 31 913 $
12/03/2022 91 248 $

Recro Pharma, Inc. capitalization e- 21/03/2022 ifinyelela kuma- 118 490 816 amadola aseMelika. 18/03/2022 Recro Pharma, Inc. capitalization ifinyeleleka 121 594 152 amadola aseMelika. Recro Pharma, Inc. capitalization yemakethe yi- $ 115 376 208 ku- 17/03/2022. Ukweqiwa kwemakethe kwe- Recro Pharma, Inc. kufinyelele ku- 115 105 368 amadola aseMelika ku- 16/03/2022.

Recro Pharma, Inc. capitalisation emakethe e- 15/03/2022 ilingana no- 112 848 400 US dollars. Recro Pharma, Inc. capitalization ifinyelela ku- 113 508 560 amadola aseMelika ku- 14/03/2022. Recro Pharma, Inc. capitalization e- 12/03/2022 ifinyelela kuma- 111 719 920 amadola aseMelika.

I-capital of Recro Pharma, Inc. namuhla ngu-118 490 816 $. Imali yemakethe yeRecro Pharma, Inc. ishintshile -2.552% uma kuqhathaniswa nezolo. Umthamo wokuhweba we REPH amasheya ka Recro Pharma, Inc. ngosuku lokuhweba lokugcina lwafinyelela ku-29 724 $. Inani lemali yokuhweba yamasheya e Recro Pharma, Inc. lishintshe ku--60.365% uma kuqhathaniswa nosuku lokuhweba olwedlule.

Izindleko zamasheya Recro Pharma, Inc.

Izezimali Recro Pharma, Inc.